

Financial Statements of

**PROTEIN INDUSTRIES
CANADA INC.**

And Independent Auditor's Report thereon

Year ended March 31, 2025

**KPMG LLP**

2000-1881 Scarth Street
Regina, SK S4P 4K9
Canada
Tel 306-791-1200
Fax 306-757-4703

INDEPENDENT AUDITOR'S REPORT

To the Members of Protein Industries Canada Inc.

Opinion

We have audited the financial statements of Protein Industries Canada Inc. (the Entity), which comprise:

- the statement of financial position as at March 31, 2025
- the statement of operations and net assets for the year then ended
- the statement of cash flows for the year then ended
- and notes to the financial statements, including a summary of significant accounting policies (hereinafter referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Entity as at March 31, 2025, and its results of operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the ***"Auditor's Responsibilities for the Audit of the Financial Statements"*** section of our auditor's report.

We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

Management is responsible for the other information. Other information comprises:

- the information, other than the financial statements and the auditor's report thereon, included in the annual report.



Page 2

Our opinion on the financial statements does not cover the other information and we do not and will not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information identified above and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit and remain alert for indications that the other information appears to be materially misstated.

We obtained the information, other than the financial statements and the auditor's report thereon, included in the annual report as at the date of this auditor's report. If, based on the work we have performed on this other information, we conclude that there is a material misstatement of this other information, we are required to report that fact in the auditor's report.

We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit.



Page 3

We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion.

The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

DRAFT

Regina, Canada

July 28, 2025

PROTEIN INDUSTRIES CANADA INC.

Statement of Financial Position

As at March 31, 2025, with comparative information for 2024

	2025	2024
Assets		
Current assets:		
Cash	\$ 20,103,238	\$ 8,654,884
Investments (note 3)	2,000,000	2,000,000
Accounts receivable and accrued receivables (note 4)	542,486	392,727
Prepaid expenses	253,772	262,665
Project advances receivable (note 5)	1,394,412	1,548,880
	24,293,908	12,859,156
Property, plant and equipment (note 6)	1,008	11,657
Intangible assets (note 7)	-	995
	\$ 24,294,916	\$ 12,871,808

Liabilities and Net Assets

Current liabilities:		
Accounts payable and accrued liabilities (note 8)	\$ 5,103,602	\$ 3,650,211
Deferred contributions (note 9)	14,868,323	5,124,086
	19,971,925	8,774,297
Net assets	4,322,991	4,097,511
Commitments (note 10)		
	\$ 24,294,916	\$ 12,871,808

See accompanying notes to financial statements.

On behalf of the Board:

 Director
 Director

PROTEIN INDUSTRIES CANADA INC.

Statement of Operations and Net Assets

Year ended March 31, 2025, with comparative information for 2024

	2025	2024
Revenue:		
Innovation, Science and Economic Development Canada (note 9)	\$ 24,955,419	\$ 12,512,136
Project management fees	1,489,858	617,003
Interest earned	530,414	493,490
Membership and registration fees	75,714	89,048
Other revenue	35,000	4,798
	27,086,405	13,716,475
Expenses:		
Technology program expenses	18,628,889	7,706,308
Salaries and benefits	3,914,304	3,938,090
Capacity building program expenses	2,000,781	724,645
Office and administration	1,230,454	1,416,488
Consulting and professional fees	717,709	374,816
Events and community engagement	357,144	324,552
Amortization	11,644	21,689
	26,860,925	14,506,588
Excess (deficiency) of revenue over expenses	225,480	(790,113)
Net assets, beginning of period	4,097,511	4,887,624
Net assets, end of period	\$ 4,322,991	\$ 4,097,511

See accompanying notes to financial statement

PROTEIN INDUSTRIES CANADA INC.

Statement of Cash Flows

Year ended March 31, 2025, with comparative information for 2024

	2025	2024
Cash provided by (used in):		
Operations		
Excess (deficiency) of revenues over expenses	\$ 225,480	\$ (790,113)
Items not involving cash:		
Accrued interest	2,597	(12,534)
Amortization of property, plant and equipment	10,649	15,046
Amortization of intangible assets	995	6,643
Loss on sale of property, plant and equipment	-	1,468
Changes in non-cash operating working capital:		
ISED Canada funding receivable	-	4,420,598
Accounts receivable and accrued receivables	(152,356)	1,810,682
Prepaid expenses	8,893	(18,612)
Project advances receivable	154,468	(1,514,189)
Accounts payable and accrued liabilities	1,453,391	(19,291,791)
Deferred contributions	<u>9,744,237</u>	<u>5,067,905</u>
	11,448,354	(10,304,897)
Investing:		
Purchase of property, plant and equipment	-	(2,184)
Purchase of investments	<u>-</u>	<u>(2,000,000)</u>
	-	(2,002,184)
Increase (decrease) in cash	11,448,354	(12,307,081)
Cash, beginning of year	8,654,884	20,961,965
Cash, end of year	<u>\$ 20,103,238</u>	<u>\$ 8,654,884</u>

See accompanying notes to financial statements.

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements

Year ended March 31, 2025

Nature of operations:

Protein Industries Canada Inc. (the "Corporation" or "PIC") is incorporated under *The Non-Profit Corporations Act, 1995 (Saskatchewan)*. The primary purpose of the Corporation is to raise funds and apply for funding from the Innovation Superclusters Initiative of Innovation, Science and Economic Development Canada (ISED).

Pursuant to a funding agreement, the Corporation receives significant funding revenue from ISED to finance the development and coordination of the Innovation Superclusters Initiative to accelerate growth in the Canadian agriculture and food processing sectors. As a result, the Corporation is dependent upon the continuance of this funding to maintain operations at their current level.

Payment by the Federal Government of the contributions for all agreements is conditional on there being a legislated appropriation for the fiscal year in which the contribution is due. The Ministers shall have the right to terminate or reduce the contribution in the event that the amount of the appropriation is reduced or denied by Parliament.

Program Streams:

PIC invests in Technology, Pan-Canadian Artificial Intelligence Strategy Commercialization Stream (PCAIS), and Capacity Programs.

1. Basis of presentation:

These financial statements are prepared in accordance with Canadian accounting standards for not-for-profit organizations outlined in Part III of the CPA Canada Handbook.

2. Significant accounting policies:

The Corporation's significant accounting policies are as follows:

(a) Revenue recognition:

The Corporation follows the deferral method of accounting for contributions. Funding from ISED is restricted to provide funding to eligible recipients for future Technology and Capacity Building programs and the payment of the Corporation's operating and capital expenditures. Restricted contributions for expenses of a future period are recorded as deferred contributions and are recognized in revenue in the year in which the related expenses are incurred. Investment income earned on deferred contributions and investments are recognized in the period in which it is earned. Unrestricted contributions and sponsorships are included in the period received if the amount to be received can be reasonably estimated and collection is reasonably assured.

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

2. Significant accounting policies (continued):

(a) Revenue recognition (continued):

The Corporation signed an amended contribution agreement with ISED Canada on July 28, 2021. The amendment increased the total contribution from \$152,843,759 to \$172,843,759. ISED Canada committed to fund the Corporation for eligible program and project costs over a 5-year period commencing in Fiscal Year 2018/19. Under the terms of the amended agreement, ISED will provide a non-repayable contribution to the Corporation for 75% of eligible internal program costs that do not exceed 15% of \$172,843,759 and 100% of PIC's portion of eligible program costs. The amended contribution agreement total is not to exceed the lesser of \$172,843,759 or 100% of total Industry Matching Funds obtained by the organization over the 5-year period.

On March 28, 2023, the Corporation signed an amended and restated contribution agreement with ISED with funding commencing April 1, 2023. The amendment increased the non-repayable contribution by a further \$123,375,000 of which a maximum of \$16,875,000 is to be used towards internal program costs and \$106,500,000 towards 100% of PIC's portion of eligible program costs. The total is not to exceed the lesser of \$123,375,000 or 100% of total Industry Matching Funds obtained by the organization over the five-year period, ending March 31, 2028.

On February 5, 2025, the Corporation signed an amendment to increase the non-repayable contribution by a further \$26,625,000 to be used towards PIC's portion of eligible program costs.

The amendment increased the total contribution from \$296,218,759 to \$319,818,843 and extended the program to a 10-year period commencing in Fiscal 2018/19 and ending March 31, 2028, of which a maximum of \$35,979,620 is to be used towards internal program costs and \$283,839,223 towards 100% of PIC's portion of eligible program costs. The total is not to exceed the lesser of \$319,818,843 or 100% of total Industry Matching Funds obtained by the organization over the ten-year period, ending March 31, 2028.

On March 11, 2025, the Corporation signed an amendment to increase the non-repayable contribution by a further \$7,000,000 for the Canadian Genomics Strategy. The amendment is for a period of six years commencing April 1, 2025, and ending March 31, 2031. A maximum of \$787,500 of the contribution can be used towards internal program costs and \$6,212,500 towards 100% of PIC's portion of eligible program costs. The total is not to exceed the lesser of \$7,000,000 or 100% of total Industry Matching Funds obtained by the organization over the six-year period, ending March 31, 2031.

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

2. Significant accounting policies (continued):

(a) Revenue recognition (continued):

The Corporation has been approved for \$30,000,000 of funding within the Pan-Canadian Artificial Intelligence Strategy Commercialization Stream (“PCAIS”) to support inclusive innovation to advance the commercialization of artificial intelligence applications in Canada. The PCAIS Contribution Agreement was signed on September 13, 2022. ISED Canada committed to fund the Corporation for eligible program and project costs over a four year period commencing in Fiscal Year 2022/23. In June 2024, the Corporation requested that the total funding within the PCAIS Stream be reduced to \$20,000,000 over the four-year period ending March 31, 2026.

On March 11, 2025, the Corporation signed an amendment to increase the non-repayable contribution by a further \$8,000,000 for the PCAIS. The amendment is for a period of five years commencing April 1, 2022, and ending March 31, 2027. A maximum of \$2,400,000 of the contribution can be used towards internal program costs and \$25,600,000 towards 100% of PIC’s portion of eligible program costs. The total is not to exceed the lesser of \$28,000,000 or 100% of total Industry Matching Funds obtained by the organization over the five-year period, ending March 31, 2027.

The amount of ISED contributions varies from year to year based on forecasted operating and project spend, and amounts may be reallocated to other fiscal years within the program term with the written approval from the Minister of ISED.

Project management fees are calculated at 4% of total eligible project costs that PIC provides reimbursement for within the Technology program. Project management fees are invoiced when PIC and the ultimate recipient sign the project cost declaration.

(b) Financial assets and liabilities:

Financial instruments are recorded at fair value on initial recognition. Subsequently, they are recorded at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Corporation has not elected to carry its financial instruments at fair value.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

2. Significant accounting policies (continued):

(b) Financial assets and liabilities (continued):

Financial assets are assessed for impairment on an annual basis at the end of the fiscal year if there are indicators of impairment. If there is an indicator of impairment, the Corporation determines if there is a significant adverse change in the expected amount or timing of future cash flows from the financial asset. If there is a significant adverse change in the expected cash flows, the carrying value of the financial asset is reduced to the highest of the present value of the expected cash flows, the amount that could be realized from selling the financial asset or the amount the Corporation expects to realize by exercising its right to any collateral. If events and circumstances reverse in a future period, an impairment loss will be reversed to the extent of the improvement, not exceeding the initial carrying value.

(c) Project advances receivable:

Project advances receivable consist of funding provided to project members in advance of eligible project costs being incurred. Advances are drawn down and recognized as revenue when a claim for eligible project costs is reconciled and approved by PIC.

(d) Property, plant and equipment:

Property, plant and equipment are stated at cost, less accumulated amortization. Amortization is provided using the straight-line method at the following annual rates:

Asset	Rate
Furniture and equipment	20-45%

(e) Intangible assets:

Intangible assets are stated at cost, less accumulated amortization. Amortization is provided using the straight-line method with an annual rate of 20%.

(f) Income taxes:

The Corporation is incorporated under *The Non-Profit Corporations Act of Saskatchewan*. Under present legislation, no income taxes are payable on reported income of such corporations.

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

2. Significant accounting policies (continued):

(g) Use of estimates:

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the year. Significant items subject to such estimates and assumptions include the valuation of accounts receivable and project advances receivable. Actual results could differ from those estimates.

(h) New accounting standards adopted:

Effective April 1, 2024, the Corporation adopted AcG 20, *Customer's Accounting for Cloud Computing Arrangements*. The Corporation has chosen the simplification approach and recognizes expenditures as expenses when services are received.

3. Investments:

Investments consist of Guaranteed Investment Certificates (GICs). PIC has a total of \$2,000,000 of GIC's; \$500,000 is invested in a 90-day redeemable GIC with a maturity date of September 27, 2025, and a 3.9% interest rate (2024 – maturity date of September 27, 2024 and a 5% interest rate) and \$1,500,000 is invested in non-redeemable GIC with a maturity date of September 27, 2025, and a 4.15% interest rate (2024 – maturity date of September 27, 2024 and a 5.2% interest rate).

4. Accounts receivable and accrued receivables:

	2025	2024
Accounts receivable	\$ 206,387	\$ 119,202
Accrued receivable – interest	9,937	12,534
Accrued receivable – projects	326,162	260,991
	\$ 542,486	\$ 392,727

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

5. Project advances receivable:

	2025	2024
Beginning balance	\$ 1,548,880	\$ 34,691
Advances paid	3,332,831	2,443,415
Costs reimbursed during the year	(3,487,299)	(929,226)
	<hr/> \$ 1,394,412	<hr/> \$ 1,548,880

6. Property, plant and equipment:

	2025	2024		
	Cost	Accumulated amortization	Net book value	Net book value
Furniture and equipment	\$ 51,864	\$ 50,856	\$ 1,008	\$ 11,657

7. Intangible assets:

	2025	2024		
	Cost	Accumulated amortization	Net book value	Net book value
Website	\$ 36,500	\$ 36,500	\$ -	\$ 995

8. Accounts payable and accrued liabilities:

	2025	2024
Accounts payable	\$ 4,454,924	\$ 3,261,972
Accrued payable – operations	374,265	388,239
Accrued payable – projects	274,413	-
	<hr/> \$ 5,103,602	<hr/> \$ 3,650,211

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

9. Deferred contributions:

Deferred contributions represent ISED funding for program costs, for the purpose of providing funding to eligible recipients for future projects and for the payment of the Corporation's subsequent years' operating expenditures. The amounts are recognized as revenue in the period the related expense is incurred.

In March 2025, the Corporation received a \$5,000, one-time payment, from Food Health and Consumer Products, an industry partner. The funding was in contribution to the costs of the CNS-SCN Symposium held in May 2025. This revenue will be recognized in May 2025 when the symposium costs are recorded.

The change in the deferred contributions balance for the Global Innovation Program is as follows:

	2025	2024
Beginning balance	\$ 3,523,186	\$ -
Funding received	27,794,656	13,780,041
Recognized as revenue during the year	(20,337,091)	(10,256,855)
	<hr/> \$ 10,980,751	<hr/> \$ 3,523,186

The change in the deferred contributions balance for the PCAIS program is as follows:

	2025	2024
Beginning balance	\$ 1,600,900	\$ 56,181
Funding received	6,900,000	3,800,000
Recognized as revenue during the year	(4,618,328)	(2,255,281)
	<hr/> \$ 3,882,572	<hr/> \$ 1,600,900

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

10. Commitments:

The Corporation is committed to an office space lease over the next three years as follows:

2026	\$ 96,000
2027	96,000
2028	96,000

The Corporation invests in projects within the Technology, Capacity and PCAIS program streams. The Canadian Genomics Strategy was added March 11, 2025. Projects are selected through a competitive process and successful proponents enter into master project agreements (MPA) outlining the terms of the investment. The allocation below is the planned allocation between streams but this may change as projects are approved. As of March 31, 2025, commitments for funding by programs and unallocated funding are as follows:

	Total committed co-investment to date	Unallocated funding
Technology program	\$ 79,246,998	\$ 40,565,502
Capacity program	5,304,077	8,008,423
Canadian Genomics Strategy	-	6,212,500
PC AIS program	14,823,476	10,776,524

11. Financial risks and concentration of risk:

The Corporation, through its financial assets and liabilities, has exposures to the following risks from its use of financial instruments:

(a) Credit risk:

Credit risk refers to the risk that a counterparty may default on its contractual obligations resulting in a financial loss. The Corporation is exposed to credit risk with respect to cash, investments, accounts receivable and accrued receivables and project advances receivable. The carrying amounts of financial assets on the statement of financial position represent the Corporation's maximum credit exposure as at March 31, 2025.

PROTEIN INDUSTRIES CANADA INC.

Notes to Financial Statements (continued)

Year ended March 31, 2025

11. Financial risks and concentration of risk (continued):

(a) Credit risk (continued):

The Corporation's accounts receivable and accrued receivables and project advances receivable amounts disclosed in the statement of financial position are net of allowance for doubtful accounts \$nil (2024 - \$nil), estimated by management of the Corporation based on previous experience and its assessment of the current economic environment. The Corporation does not have significant exposure to any individual customer and has not incurred any significant bad debts during the year. The credit risk on cash and investments are limited because the counterparties are chartered banks with high credit ratings assigned by national credit-rating agencies. There has been no change to the risk exposure since the prior period.

(b) Liquidity risk:

Liquidity risk is the risk that the Corporation will be unable to fulfill its obligations on a timely basis or at a reasonable cost. The Corporation manages its liquidity risk by monitoring its operating requirements. The Corporation prepares budget and cash forecasts to ensure it has sufficient funds to fulfill its obligations. There has been no change to the risk exposure since the prior period.



Jolene Anton, CPA, CA
Partner
(306) 791-1233
janton@kpmg.ca

kpmg.com/ca/privateenterprise

The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation.

© 2024 KPMG LLP, an Ontario limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.